Product Introduction
Bioactivity


英文名: Idarubicin

描述: Idarubicin 是一种有效的、具有口服活性的蒽环类抗白血病剂。Idarubicin 抑制拓扑异构酶 II，干扰 DNA 复制和 RNA 转录。Idarubicin 可诱导 DNA 损伤。Idarubicin 抑制 DNA 合成和 c-myc 表达。Idarubicin 还抑制细菌和酵母菌的生长。

体外活性: The IC 50 of idarubicin is 3.3 ± 0.4 ng/mL on MCF-7 monolayers and 7.9 ± 1.1 ng/mL in multicellular spheroids [1]. Idarubicin exhibits a greater cytotoxicity than daunorubicin or doxorubicin in various in vitro systems. This has been attributed to a better ability of idarubicin to induce the formation of topoisomerase II -mediated DNA breaks [2]. Idarubicin is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively [3]. Idarubicin produces a concentration-dependent reduction in MCF-7 cell growth, with an IC 50 of approximately 0.01 μM. Idarubicin produces a concentration-dependent inhibition of DNA synthesis and a time- and concentration-dependent suppression of c-myc expression [4].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: Compound T4791 | Idarubicin